# Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

> **NCT01229410** · PHASE1 · COMPLETED · sponsor: **Allergan** · enrollment: 24 (actual)

## Conditions studied

- Vitrectomy

## Interventions

- **DRUG:** 400 µg Brimonidine Tartrate Implant
- **DRUG:** 200 µg Brimonidine Tartrate Implant

## Key facts

- **NCT ID:** NCT01229410
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-05
- **Final completion:** 2011-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2013-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229410, "Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01229410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*